Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function
Erik J.M. van Bommel(Amsterdam University Medical Centers), Daniël H. van Raalte(Amsterdam University Medical Centers), David Z.I. Cherney(University Health Network), Audrey Koitka‐Weber(Boehringer Ingelheim (Germany)), Jaap A. Joles(University Medical Center Utrecht), Nora Fagan(Boehringer Ingelheim (United States)), Bruce A. Perkins(Sinai Health System), Yuliya Lytvyn(University Health Network), Nima Soleymanlou(Boehringer Ingelheim (Canada))
Cited by 46
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography
|Nature Medicine|2018|750
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470